Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | XDH | P47989 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | TPMT | P51580 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114318 | 0.88 | KMT2A (0.61) | CNR2LMNAXDHKDM4EPOLB | |
| SCHEMBL1919075 | 0.86 | KDM4E (0.72) | CNR2LMNAXDHKDM4EPOLB | |
| SCHEMBL1465618 | 0.85 | KDM4E (0.77) | CNR2LMNAXDHKDM4EPOLB | |
| SCHEMBL30594704 | 0.85 | KDM4E (0.77) | CNR2LMNAXDHKDM4EPOLB | |
| SCHEMBL23270854 | 0.84 | HSD17B2 (0.67) | CNR2KDM4EPOLBGAACA12 | |
| SCHEMBL1134668 | 0.83 | TPMT (0.73) | CNR2LMNAXDHKDM4EPOLB | |
| SCHEMBL18969524 | 0.83 | KMT2A (0.51) | CNR2LMNAXDHKDM4EPOLB | |
| SCHEMBL56960 | 0.83 | PTGS2 (0.72) | CNR2LMNAKDM4EPOLBFUT7 | |
| SCHEMBL14448996 | 0.81 | LMNA (0.64) | CNR2LMNAXDHKDM4EPOLB | |
| SCHEMBL26395218 | 0.81 | POLB (0.65) | CNR2LMNAXDHKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298163-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEIGENE, LTD. (KY) | 2022-09-22 | — | — | US | disclosed |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BEIGENE, LTD. (KY) | 2022-07-05 | — | — | US | disclosed |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BEIGENE, LTD. (KY) | 2022-07-05 | — | — | US | disclosed |
| US-20200181150-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEONE MEDICINES I GMBH (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200181150-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEONE MEDICINES I GMBH (CH) | 2020-06-11 | — | — | US | disclosed |
| CN-110997677-A | Btk inhibitors with improved dual selectivity | 百济神州有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019034009-A1 | Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEIGENE, LTD. (KY) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034009-A1 | Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BEIGENE, LTD. (KY) | 2019-02-21 | — | — | WO | disclosed |
| US-7067665-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-27 | — | — | US | disclosed |
| US-6953857-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or viia | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1349847-B1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| CN-1481376-A | HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS | ���ĵ�˹ҩ��¹�����˾ | 2004-03-10 | — | — | CN | disclosed |
| EP-1349847-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-10-08 | — | — | EP | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298163-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BTK, SYK, LYN | CNR2 2997/4885LMNA 4418/4885XDH 3784/4885 |
| US-20200181150-A1 | BTK INHIBITORS WITH IMPROVED DUAL SELECTIVITY | BTK, SYK, LYN | CNR2 2997/4885LMNA 4418/4885XDH 3784/4885 |
| US-11377449-B2 | BTK inhibitors with improved dual selectivity | BTK, SYK, LYN | CNR2 2997/4885LMNA 4418/4885XDH 3784/4885 |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | F12, F11, F5 | CNR2 912/4885LMNA 59/4885XDH 17/4885 |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | CNR2 489/4885LMNA 324/4885XDH 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.